ANKRD6

Across TCGA pan-cancer cohorts, ANKRD6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANKRD6 data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANKRD6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRD6 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LUAD, LSCC, and GBM are the cancer types where ANKRD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.409	0.941	.010	9	view →
LSCC	OS	Tertile	All	1.000	0.610	.027	2	view →
GBM	OS	Median	All	1.000	0.717	.049	1	view →
CCRCC	OS	Quartile	All	0.808	1.000	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ANKRD6–LUAD (DFS)

Open the LUAD breakdown →